● Recruiting

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Condition: Advanced Solid Tumor · Sponsor: LaNova Medicines Limited

PhasePhase 1/Phase 2

Planned participants320

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.

This description comes directly from the study's public registry record.

Talk to the study team

Alex Yuan · +8615901815211 · alexyuan@lanovamed.com

Paul Kong · +8613564682439 · paulkong@lanovamed.com

Always discuss trial participation with your own doctor first.

Locations (1)

FuDan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06682780